Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where NOTV declined for three days, in of 320 cases, the price declined further within the following month. The odds of a continued downward trend are .
The 10-day RSI Indicator for NOTV moved out of overbought territory on December 18, 2024. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Moving Average Convergence Divergence Histogram (MACD) for NOTV turned negative on December 19, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at .
NOTV broke above its upper Bollinger Band on December 13, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Momentum Indicator moved above the 0 level on December 20, 2024. You may want to consider a long position or call options on NOTV as a result. In of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where NOTV advanced for three days, in of 305 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 214 cases where NOTV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NOTV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.002) is normal, around the industry mean (23.300). P/E Ratio (169.492) is within average values for comparable stocks, (83.485). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.433) is also within normal values, averaging (43.338).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NOTV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
a provider of drug discovery and development services
Industry MedicalSpecialties
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
APDSX | 36.21 | 0.35 | +0.98% |
Artisan Small Cap Advisor | |||
HTECX | 22.99 | 0.22 | +0.97% |
Hennessy Technology Investor | |||
NELIX | 61.67 | 0.48 | +0.78% |
Nuveen Equity Long/Short I | |||
HFQAX | 5.98 | 0.02 | +0.34% |
Janus Henderson Global Equity Income A | |||
TBWCX | 17.40 | -0.02 | -0.11% |
Thornburg Better World International C |
A.I.dvisor indicates that over the last year, NOTV has been loosely correlated with RGEN. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if NOTV jumps, then RGEN could also see price increases.
Ticker / NAME | Correlation To NOTV | 1D Price Change % | ||
---|---|---|---|---|
NOTV | 100% | +6.25% | ||
RGEN - NOTV | 36% Loosely correlated | -1.42% | ||
AKYA - NOTV | 31% Poorly correlated | -2.35% | ||
CRL - NOTV | 30% Poorly correlated | +1.99% | ||
CDNA - NOTV | 28% Poorly correlated | +0.29% | ||
BVS - NOTV | 28% Poorly correlated | +1.43% | ||
More |